Dr. Kideckel, who is an accomplished Doctor and an MBA, and who wrote Beacon Securities' glowing investment analysis report on RVX, would be leagues apon leagues better at running Resverlogix.  He just got hired by Winnipeg-based Delta 9 Cannabis to lead their corporate development and capital markets intiatives.  Wow, could we ever use that!  We surely need his many applicable skills and talents and his scientific training and stellar credentials.  Maybe we can interest him by reminding him of the billion plus revenue potential at RVX that he talked about.   Delta 9, which I am also invested in, brings in sales of 60 million a year with potential to double/triple that in the next couple of years but that would be about tops.  It would be great if we could eventually poach Dr. Kideckel.  I'd give him a call today if I were 'you know who'.  I can't even say his name anymore I am so disgusted.

Delta 9 Appoints David Kideckel as Head of Strategy, Corporate Development & Capital Markets

Capital Markets & Pharmaceuticals Veteran to Lead Company’s Next Phase of Domestic & International Expansion

WINNIPEG, MB – August 16, 2021 – DELTA 9 CANNABIS INC. (TSX: DN) (OTCQX: DLTNF) (“Delta 9” or the “Company”), is pleased to announce that it has appointed Dr. David Kideckel, PhD, MBA as Executive Vice President, Head of Strategy, Corporate Development & Capital Markets. This is a newly created position to lead the Company’s next phase of growth expansion.

David joins Delta 9 after nearly 20 years of combined industry and capital markets experience, most recently serving as Managing Director, Senior Institutional Equity Research Analyst at ATB Capital Markets. David’s industry experience spans several senior healthcare executive roles including at Johnson & Johnson Inc. and Alexion Pharmaceuticals (acquired by AstraZeneca). Within Capital Markets, David was at the forefront of the cannabis industry and was the sole Bay Street analyst to cover GW Pharmaceuticals (acquired by Jazz Pharmaceuticals), and was known for his expert analyses and thought leadership in retail, LP’s, US & international strategy & partnerships, as well as cannabinoid-derived pharmaceuticals and biosynthesis.

"I am extremely pleased to welcome David to our team, propelling our capital markets strategy and reach, through his wealth of experience. David was one of the leading cannabis analysts and has an exceptional network of contacts with an in-depth knowledge of the cannabis industry and its subsectors. David’s appointment reflects our commitment to having best-in-class talent to advance the Company’s growth trajectory strategically and expeditiously," said John Arbuthnot, CEO of Delta 9.

“Of all the companies I have evaluated over the last several years, Delta 9 has incredible potential and I’m proud to join a seasoned team that is on the verge of steady and continuous growth within an explosive industry,” said David Kideckel, Delta 9 EVP, Head of Strategy, Corporate Development & Capital Markets.

For more information contact:
Investor & Media Contact:
Ian Chadsey VP Corporate Affairs
Mobile: 204-898-7722
E-mail: ian.chadsey@delta9.ca